Environmental cephalosporin-resistant gram-negative bacteria: what is lurking beyond the hospital doors?
DOI:
https://doi.org/10.3396/ijic.v21.23791Keywords:
environmental contamination, Brucella, Ochrobactrum, Acinetobacter, carbapenem resistanceAbstract
Antibiotic resistant Gram-negative bacilli are being increasingly recognized in community-onset infections. Concerns have been raised regarding environmental surfaces as reservoirs for multidrug-resistant pathogens; in particular, community wastewater samples have been found to harbor cephalosporin- and carbapenem-resistant Enterobacterales. In this report, we used selective media to culture cephalosporin-resistant Gram-negative bacilli from high-touch surfaces in the environment surrounding hospitals in New York City. Of the 336 surfaces swabbed, 66 grew cephalosporin-resistant Gram-negative bacteria. No Enterobacterales were isolated. The most common isolate was Brucella (Ochrobactrum) spp., accounting for 26 of the 66 positive cultures; 19 originated from surfaces near two hospitals. One isolate of Brucella (Ochrobactrum) spp. was found to possess blaOXA-24. Acinetobacter spp. accounted for 12 of the 66 positive cultures. Forty cultures obtained with saline-saturated gauze were obtained at public transportation centers near hospitals; a comparable 40 cultures were obtained at transportation centers distant from hospitals. Of the 38 positive cultures from transportation surfaces near medical centers, 15 grew Brucella (Ochrobactrum) spp. In comparison, Brucella (Ochrobactrum) spp. accounted for only five of the 33 positive transportation cultures distant from medical centers (P = 0.03). Again, none of the cultures grew Enterobacterales. It is reassuring that dried environmental surfaces around hospitals did not contain resistant Enterobacterales. However, Brucella (Ochrobactrum) spp. was widespread and territorial and may be a reservoir for OXA-type carbapenemases.
Downloads
References
1. CDC. Antibiotic resistance threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.
2. Cocker D, Chidziwisano K, Mphasa M, Mwapasa T, Lewis JM, Rowlingson B, et al. Investigating One Health risks for human colonisation with extended spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Malawian households: a longitudinal cohort study. Lancet Microbe 2023; 4: e534–43. doi: 10.1016/S2666-5247(23)00062-9
3. Paumier A, Asquier-Khati A, Thibaut S, Coeffic T, Lemenand O, Larramendy S, et al. Assessment of factors associated with community-acquired extended-spectrum β-lactamase-producing Escherichia coli urinary tract infections in France. JAMA Netw Open 2022; 5: e2232679. doi: 10.1001/jamanetworkopen.2022.32679
4. Lee J, Sunny S, Nazarian E, Fornek M, Abdallah M, Episcopia B, et al. Carbapenem-resistant Klebsiella pneumoniae in large public acute-care healthcare system, New York, New York, USA, 2016–2022. Emerg Infect Dis 2023; 29: 1973–8. doi: 10.3201/eid2910.230153
5. Islam MA, Islam M, Hasan R, Hossain MI, Nabi A, Rahman M, et al. Environmental spread of New Delhi metallo-β-Lactamase-1-producing multidrug-resistant bacteria in Dhaka, Bangladesh. Appl Environ Microbiol 2017; 83: e00793-17. doi: 10.1128/AEM.00793-17
6. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011; 11: 355–62. doi: 10.1016/S1473-3099(11)70059-7
7. Jawad A, Seifert H, Snelling AM, Heritage J, Hawkey PM. Survival of Acinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates. J Clin Microbiol 1998; 36: 1938–41. doi: 10.1128/JCM.36.7.1938-1941
8. Fahy S, O’Connor JA, Lucey B, Sleator RD. Hospital reservoirs of multidrug resistant Acinetobacter species-The elephant in the room! Br J Biomed Sci 2023; 80: 11098. doi: 10.3389/bjbs.2023.11098
9. Antunes LC, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen. Pathog Dis 2014; 71: 292–301. doi: 10.1111/2049-632X.12125
10. Joly-Guillou, M-L. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 2005; 11: 868–73. doi: 10.1111/j.1469-0691.2005.01227
11. Saati-Santamaría Z, Baroncelli R, Rivas R, García-Fraile P. Comparative genomics of the genus Pseudomonas reveals host- and environment-specific evolution. Microbiol Spectr 2022; 10: e0237022. doi: 10.1128/spectrum.02370-22
12. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 2012; 25: 2–41. doi: 10.1128/cmr.00019-11
13. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 28th informational supplement, M100-S33. Wayne, PA: CLSI; 2023.
14. Srinivasan R, Karaoz U, Volegova M, MacKichan J, Kato-Maeda M, Miller M, et al. Use of 16S rRNA gene for identification of a broad range of clinically relevant bacterial pathogens. PLoS One 2015; 10: e0117617. doi: 10.1371/journal.pone.0117617
15. Asrat H, Samaroo-Campbell J, Ata S, Quale J. Contribution of iron-transport systems and β-lactamases to cefiderocol resistance in clinical isolates of Acinetobacter baumannii endemic to New York City. Antimicrob Agents Chemother 2023; 67: e0023423. doi: 10.1128/aac.00234-23
16. Muzslay M, Moore G, Alhussaini N, Wilson APR. ESBL-producing Gram-negative organisms in the healthcare environment as a source of genetic material for resistance in human infections. J Hosp Infect 2017; 95: 59–64. doi: 10.1016/j.jhin.2016.09.009
17. Mills MC, Lee J. The threat of carbapenem-resistant bacteria in the environment: evidence of widespread contamination of reservoirs at a global scale. Environ Pollut 2019; 255: 113143. doi: 10.1016/j.envpol.2019.113143
18. McDonald LC, Banerjee SN, Jarvis WR. Seasonal variation of acinetobacter infections: 1987–1996. Nosocomial Infections Surveillance System. Clin Infect Dis 1999; 29: 1133–7. doi: 10.1086/313441
19. Moreno E, Blasco JM, Letesson JJ, Gorvel JP, Moriyón I. Pathogenicity and its implications in taxonomy: the Brucella and Ochrobactrum case. Pathogens 2022; 11: 377. doi: 10.3390/pathogens11030377
20. Moreno E, Middlebrook EA, Altamirano-Silva P, Al Dahouk S, Araj GF, Arce-Gorvel V, et al. If you’re not confused, you’re not paying attention: Ochrobactrum is not Brucella. J Clin Microbiol 2023; 61: e0043823. doi: 10.1128/jcm.00438-23
21. American Society for Microbiology. Brucella and Ochrobactrum taxonomic updates for laboratories. Available from: ASM.org [cited 15 February 2024].
22. Gohil K, Rajput V, Dharne M. Pan-genomics of Ochrobactrum species from clinical and environmental origins reveals distinct populations and possible links. Genomics 2020; 112: 3003–12. doi: 10.1016/j.ygeno.2020.04.030
23. Ryan MP, Pembroke JT. The genus Ochrobactrum as major opportunistic pathogens. Microorganisms 2020; 8: 1797. doi: 10.3390/microorganisms8111797
24. Thoma B, Straube E, Scholz HC, Dahouk SA, Zöller L, Pfeffer M, et al. Identification and antimicrobial susceptibilities of Ochrobactrum spp. Int J Med Microbiol 2009; 299: 209–20. doi: 10.1016/j.ijmm.2008.06.009
25. Bou G, Oliver A, Martínez-Beltrán J. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob Agents Chemother 2000; 44: 1556–61. doi: 10.1128/AAC.44.6.1556-1561.2000
26. Lasarte-Monterrubio C, Guijarro-Sánchez P, Bellés A, Vázquez-Ucha JC, Arca-Suárez J, Fernández-Lozano C, et al. Carbapenem resistance in Acinetobacter nosocomialis and Acinetobacter junii conferred by acquisition of blaOXA-24/40 and genetic characterization of the transmission mechanism between Acinetobacter genomic species. Microbiol Spectr 2022; 10: e0273421. doi: 10.1128/spectrum.02734-21
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Yasna Yusuf, Olubosede Awoyomi, Alison Bradbury, Yongsheng Wang, Briana Episcopia, Marie Abdallah, John Quale
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright of their work, with first publication rights granted to IJIC. Read the full Copyright- and Licensing Statement.
